You are here:

fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra)


Following a full submission

Fondaparinux (Arixtra) is not recommended for use within NHS Scotland for the prevention of venous thromboembolic events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as those undergoing abdominal cancer surgery.

Fondaparinux showed non-inferiority to one other low molecular weight heparin in preventing VTE in patients undergoing abdominal surgery. The economic case has not been demonstrated.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra)
SMC Drug ID: 287/06
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Prevention of venous thromboembolic events
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 7 August 2006